Squarepoint Ops LLC Rapt Therapeutics, Inc. Transaction History

Squarepoint Ops LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.89 - $9.38 $312,102 - $1.01 Million	107,994 New	107,994 $329,000
Q1 2022 May 16, 2022	SELL	$17.02 - $40.22 $192,938 - $455,933	-11,336 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$29.5 - $39.5 $413,678 - $553,908	-14,023 Reduced 55.3%	11,336 $416,000
Q3 2021 Nov 15, 2021	BUY	$29.86 - $39.47 $395,854 - $523,253	13,257 Added 109.54%	25,359 $787,000
Q2 2021 Aug 16, 2021	SELL	$17.99 - $40.02 $8,365 - $18,609	-465 Reduced 3.7%	12,102 $385,000
Q1 2021 May 17, 2021	SELL	$16.0 - $24.46 $247,840 - $378,885	-15,490 Reduced 55.21%	12,567 $279,000
Q4 2020 Feb 16, 2021	BUY	$15.89 - $40.87 $445,825 - $1.15 Million	28,057 New	28,057 $554,000
Q3 2020 Nov 16, 2020	SELL	$21.6 - $37.5 $4.58 Million - $7.95 Million	-212,016 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$14.16 - $32.85 $2.74 Million - $6.35 Million	193,392 Added 1038.4%	212,016 $12.6 Million
Q1 2020 May 15, 2020	BUY	$11.86 - $48.86 $220,880 - $909,968	18,624 New	18,624 $396,000

104

27.1M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $24.6M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.